1 |
FDA, Guidance for Industry - Immediate release solid oml dosage forms; scale-up and postapproval changes: chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, November 1995
|
2 |
FDA, Guidance for Industry - SUPAC-MR: Modified release solid oml dosage forms; Scale-up and postapproval changes: chemistry, manufacturing and controls, in vitro dissolution testing and in vivo bioequivalence docmnentation, September 1997
|
3 |
H. Sah, M. Cho, SA Park, MD. Yun and SJ. Kang, Application of SUPAC-MR in processing postapproval changes to modified release solid oml dosage forms, J. Kay. Pharm. Sci., 34, 229-254 (2004)
|
4 |
FDA, Guidance for Industry - SUPAC-SS: Nonsterile semisolid dosage forms; Scale-up and postapproval changes: chemistry, manufacturing and controls; In vitro release testing and in vivo bioequivalence docmnentation, May 1997
|
5 |
M. Cho, KD. Suk and H. Sah, Usefulness of SUPAC-SS in dealing with postapproval changes to semisolid dosage forms, J. Kay. Pharm. Sci., 35, 207-224 (2005)
|
6 |
Commission Regulation (EC) No. 1085/2003, June 2003
|
7 |
European Commission, Notice to applicants, Volume 2A Procedure for marketing authorisation, Chapter 5. Variations, February 2004
|
8 |
EMEA, Post-authorisation guidance for human medicinal products, August 2006
|
9 |
H. Sah, SA Park, M.O. Yun and S1. Kang, Scrutiny made to SUPAC-IR dealing with postapproval changes in immediate release solid oral dosage forms, J. Kay. Pharm. Sci., 34, 57-71 (2004)
|
10 |
FDA, Guidance for Industry - Changes to an approved NDA or ANDA, April 2004
|
11 |
ICH Harmonised Tripartite Guideline, Pharmaceutical development Q8, November 2005
|
12 |
European Commission, Guideline on the categorisation of new applications (NA) versus variations applications (V), January 2002
|
13 |
EMEA, Annual report of the European Medicines Agency 2005
|
14 |
EMEA, Tenth annual report of the European Medicines Agency 2004
|
15 |
EMEA, Ninth annual report of the European Medicines Agency 2003
|
16 |
EMEA, Eighth annual report of the European Medicines Agency 2002
|
17 |
EMEA, Seventh annual report of the European Medicines Agency 2001
|
18 |
식품의약품안전청, 식품의약품안전청 고시 제2006-41호 개정, 2006년 9월
|